Citadel Advisors’s Provectus Biopharmaceuticals PVCT Stock Holding History
Bought
Maintained
Sold
Other funds holding PVCT
SM
Citadel Advisors's PVCT Position: Q3 2016 in Review
Citadel Advisors sold out of Provectus Biopharmaceuticals (PVCT) in Q3 2016, closing a stake of 178,100 shares — an estimated $66K sold.
Citadel Advisors first reported a position in PVCT in Q2 2014 and held it in 6 quarters. The position peaked at $99K in Q1 2016. 41 funds tracked by Wall St. Rank hold PVCT as of Q3 2016.
- Citadel Advisors reported no remaining Provectus Biopharmaceuticals position as of Q3 2016 after selling out during the quarter.
- Citadel Advisors sold 178,100 Provectus Biopharmaceuticals shares in Q3 2016, an estimated $66K.
- Citadel Advisors first reported a position in Provectus Biopharmaceuticals in Q2 2014 and held it in 6 quarters.
- Citadel Advisors's Provectus Biopharmaceuticals position peaked at $99K in Q1 2016.
- 41 funds tracked by Wall St. Rank held Provectus Biopharmaceuticals as of Q3 2016.
Based on Citadel Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.